Xenetic Biosciences, Inc. (XBIO)

Xenetic Biosciences Statistics

Total Valuation

XBIO has a market cap or net worth of $8.79 million. The enterprise value is $3.76 million.

Market Cap	8.79M
Enterprise Value	3.76M

Important Dates

The next estimated earnings date is Tuesday, November 11, 2025, after market close.

Earnings Date	Nov 11, 2025
Ex-Dividend Date	n/a

Share Statistics

XBIO has 2.28 million shares outstanding. The number of shares has increased by 0.25% in one year.

Current Share Class	2.28M
Shares Outstanding	2.28M
Shares Change (YoY)	+0.25%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	4.67%
Owned by Institutions (%)	3.25%
Float	1.92M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2.34
Forward PS	6.34
PB Ratio	1.29
P/TBV Ratio	1.92
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	1.54
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 5.93

Current Ratio	5.93
Quick Ratio	5.29
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -51.83% and return on invested capital (ROIC) is -34.31%.

Return on Equity (ROE)	-51.83%
Return on Assets (ROA)	-28.37%
Return on Invested Capital (ROIC)	-34.31%
Return on Capital Employed (ROCE)	-73.38%
Revenue Per Employee	$1.22M
Profits Per Employee	-$1.54M
Employee Count	2
Asset Turnover	0.34
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +3.58% in the last 52 weeks. The beta is 2.44, so XBIO's price volatility has been higher than the market average.

Beta (5Y)	2.44
52-Week Price Change	+3.58%
50-Day Moving Average	3.67
200-Day Moving Average	3.46
Relative Strength Index (RSI)	46.13
Average Volume (20 Days)	2,542,174

Short Selling Information

The latest short interest is 16,909, so 0.74% of the outstanding shares have been sold short.

Short Interest	16,909
Short Previous Month	23,478
Short % of Shares Out	0.74%
Short % of Float	0.88%
Short Ratio (days to cover)	1.21

Income Statement

In the last 12 months, XBIO had revenue of $2.45 million and -$3.08 million in losses. Loss per share was -$2.00.

Revenue	2.45M
Gross Profit	2.45M
Operating Income	-3.27M
Pretax Income	-3.08M
Net Income	-3.08M
EBITDA	n/a
EBIT	-3.27M
Loss Per Share	-$2.00

Balance Sheet

The company has $4.78 million in cash and n/a in debt, giving a net cash position of $4.78 million or $2.10 per share.

Cash & Cash Equivalents	4.78M
Total Debt	n/a
Net Cash	4.78M
Net Cash Per Share	$2.10
Equity (Book Value)	4.45M
Book Value Per Share	2.88
Working Capital	4.45M

Cash Flow

Operating Cash Flow	-2.52M
Capital Expenditures	n/a
Free Cash Flow	-2.52M
FCF Per Share	-$1.11

Margins

Gross margin is 100.00%, with operating and profit margins of -133.49% and -126.03%.

Gross Margin	100.00%
Operating Margin	-133.49%
Pretax Margin	-126.03%
Profit Margin	-126.03%
EBITDA Margin	n/a
EBIT Margin	-133.49%
FCF Margin	n/a

Dividends & Yields

XBIO does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.25%
Shareholder Yield	-0.25%
Earnings Yield	-36.10%
FCF Yield	-29.50%

Analyst Forecast

Price Target	n/a
Price Target Difference	n/a
Analyst Consensus	Hold
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on May 15, 2023. It was a reverse split with a ratio of 1:10.

Last Split Date	May 15, 2023
Split Type	Reverse
Split Ratio	1:10

Scores

XBIO has an Altman Z-Score of -48.75 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-48.75
Piotroski F-Score	3